论文部分内容阅读
目的探讨肌球蛋白轻链激酶(MYLK)mRNA在非小细胞肺癌(NSCLC)患者外周血的表达情况及其与临床特征的关系。方法 48例NSCLC患者(肺癌组)和48例非肿瘤患者(对照组),抽取静脉血后分离出单个核细胞,使用实时荧光定量PCR检测MYLK mRNA的表达情况,并分析其表达量与临床特征的关系。结果肺癌组及对照组患者外周血均有MYLK mRNA表达,肺癌组患者MYLK mRNA表达量为(1.40±0.57),明显低于对照组的(2.03±0.16)(P<0.05);术前组与术后组、鳞癌组与腺癌组、高+中分化组与低分化组、男性组与女性组、吸烟组与不吸烟组的MYLK mRNA相对表达量比较,差异均无统计学意义(P均>0.05);Ⅲ+Ⅳ期组患者、有淋巴结转移组患者MYLK mRNA相对表达量分别高于Ⅰ+Ⅱ期组、无淋巴结转移组患者(P<0.05)。结论外周血MYLK mRNA的表达水平可能与NSCLC发生发展有关,对判断NSCLC预后有一定价值。
Objective To investigate the expression of myosin light chain kinase (MYLK) mRNA in peripheral blood of patients with non-small cell lung cancer (NSCLC) and its relationship with clinical features. Methods 48 cases of NSCLC patients (lung cancer group) and 48 non-tumor patients (control group) were enrolled in this study. Mononuclear cells were isolated from venous blood and MYLK mRNA expression was detected by real-time fluorescence quantitative PCR. The expression level and clinical features Relationship. Results The expression of MYLK mRNA in lung cancer group and control group was significantly lower than that in control group (1.40 ± 0.57, 2.03 ± 0.16, P <0.05) There was no significant difference in MYLK mRNA expression between postoperative group, squamous cell carcinoma and adenocarcinoma group, high + moderately differentiated group and poorly differentiated group, male and female group, smoking group and no smoking group (P (All P> 0.05). The relative expression of MYLK mRNA in stage Ⅲ + Ⅳ patients with lymph node metastasis was higher than that in stage Ⅰ + Ⅱ and without lymph node metastasis (P <0.05). Conclusion The expression of MYLK mRNA in peripheral blood may be related to the development and progression of NSCLC, which may be of value in judging the prognosis of NSCLC.